Kadmon Holdings Inc (NASDAQ:KDMN) released its earnings results on Thursday. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.05, Briefing.com reports. The firm had revenue of $3 million for the quarter, compared to analyst estimates of $3.46 million. During the same period last year, the business earned ($4.40) earnings per share. The firm’s quarterly revenue was down 53.1% compared to the same quarter last year.

Shares of Kadmon Holdings (KDMN) traded down 2.22% on Friday, reaching $2.20. 268,617 shares of the company’s stock were exchanged. Kadmon Holdings has a 12 month low of $2.19 and a 12 month high of $10.48. The firm’s 50-day moving average price is $3.21 and its 200 day moving average price is $3.28. The company’s market cap is $114.06 million.

In other Kadmon Holdings news, major shareholder Goldentree Asset Management Lp sold 349,661 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $2.60, for a total transaction of $909,118.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 1,840,331 shares of company stock worth $6,193,607.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/05/kadmon-holdings-inc-nasdaqkdmn-issues-earnings-results-beats-expectations-by-0-05-eps.html.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research downgraded Kadmon Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. ValuEngine downgraded Kadmon Holdings from a “sell” rating to a “strong sell” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Kadmon Holdings in a research report on Monday, June 26th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $7.00 target price on shares of Kadmon Holdings in a research report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $9.93.

About Kadmon Holdings

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.